MSH Release-Inhibiting Factor (trifluoroacetate salt)
(Synonyms: Melanocyte-stimulating Hormone Release-Inhibiting Factor; MIF-1; MSH-R-IF) 目录号 : GC91914MSH Release-Inhibiting Factor (trifluoroacetate salt) (MSH-R-IF)是一种与大鼠纹状体结合的下丘脑三肽（Kd = 4.69 nM），具有多种生物活性。
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
MSH release-inhibiting factor (MSH-R-IF) is a hypothalamic tripeptide that binds to rat striatum (Kd = 4.69 nM) and has diverse biological activities.1,2,3,4 In vivo, MSH-R-IF (0.1 mg/kg) decreases immobility of mice in the forced swim test, indicating antidepressant-like activity.2 MSH-R-IF (20 mg/kg) increases striatal concentration of dopamine and the dopamine metabolites DOPAC, 3-methoxy tyramine (3-MT), and homovanillic acid (HVA) in a mouse model of Parkinson's disease induced by MPTP.3 It decreases vacuous chewing movements induced by haloperidol in a rat model of tardive dyskinesia when administered at a dose of 2 mg/kg.4 MSH-R-IF also has anti-opiate effects, reversing analgesia induced by morphine and an enkephalin in mice in a radiant heat tail-flick assay.1
References:
[1]. Pan, W., and Kastin, A.J.From MIF-1 to endomorphin: The Tyr-MIF-1 family of peptidesPeptides28(12)2411-2434(2007).
[2]. Kastin, A.J., Abel, D.A., Ehrensing, R.H., et al.Tyr-MIF-1 and MIF-1 are active in the water wheel test for antidepressant drugsPharmacol. Biochem. Behav.21(5)767-771(1984).
[3]. Marcotte, E.R., Chugh, A., Mishra, R.K., et al.Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)Peptides19(2)403-406(1998).
[4]. Sharma, S., Paladino, P., Gabriele, J., et al.Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesiaPeptides24(2)313-319(2003).
| Cas No. | SDF | ||
| 别名 | Melanocyte-stimulating Hormone Release-Inhibiting Factor; MIF-1; MSH-R-IF | ||
| 化学名 | L-prolyl-L-leucyl-glycinamide, trifluoroacetate salt | ||
| Canonical SMILES | O=C([C@@H](NC([C@H]1NCCC1)=O)CC(C)C)NCC(N)=O.FC(F)(C(O)=O)F | ||
| 分子式 | C13H24N4O3 ? XCF3COOH | 分子量 | 284.4 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5162 mL | 17.5809 mL | 35.1617 mL |
| 5 mM | 0.7032 mL | 3.5162 mL | 7.0323 mL |
| 10 mM | 0.3516 mL | 1.7581 mL | 3.5162 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet